

## LIST OF PEPTIDE API

| Molecules*                  | Therapeutic class                            | Stage                                      | Commercial For |
|-----------------------------|--|--|----------------|
| Leuprorelin Acetate USP     | GnRH agonist and an antineoplastic agent     | Commercial                                 | RoW            |
| Octreotide Acetate USP      | Treatment of Acromegaly and Carcinoid Tumors | Commercial                                 | RoW            |
| Ganirelix Acetate           | GnRH antagonist                              | Commercial                                 | RoW            |
| Triptorelin Pamoate/Acetate | GnRH agonist and an antineoplastic agent     | Commercial                                 | RoW            |
| Cetrorelix Acetate          | GnRH antagonist and an antineoplastic agent  | Commercial                                 | RoW            |
| Degarelix Acetate           | GnRH antagonist and an antineoplastic agent  | Commercial                                 | RoW            |
| Goserelin acetate           | GnRH antagonist and an antineoplastic agent  | Commercial                                 | RoW            |
| Sincalide                   | Secretagogues                                | Under Development                          | —              |
| Desmopressin                | Anti-diuretic Hormone                        | Commercial                                 | RoW            |
| Exenatide                   | Antidiabetic GLP1 receptor agonist           | Commercial                                 | RoW            |
| Liraglutide                 | Type II anti-Diabetic                        | Under Development                          | —              |
| Carfilzomib                 | Anticancer                                   | Development completed,<br>Tech transferred | —              |
| Linaclotide                 | Constipation treatment                       | Under Development                          | —              |
| Vasopressin                 | Antidiuretic hormone                         | Commercial                                 | RoW            |
| Plecanatide                 | Constipation treatment                       | Under Development                          | —              |
| Abaloparatide               | Osteoporosis treatment                       | Under Development                          | —              |
| Semaglutide                 | Type II anti-Diabetic                        | Under Development                          | —              |
| Teriparatide                | Treatment of osteoporosis                    | Commercial                                 | RoW            |
| Lanreotide Acetate          | Treatment of Acromegaly                      | Under Development                          | —              |
| Setmelanotide               | Chronic weight management                    | Under Development                          | —              |
| Tirzepatide                 | Type II anti-Diabetic                        | Under Development                          | —              |
| Terlipressin Acetate        | Vasopressin agonist                          | Commercial                                 | RoW            |
| Carbetocin                  | Uterotonic Agent                             | Commercial                                 | RoW            |
| Felypressin                 | Anti-diuretic Hormone                        | Under Development                          | —              |
| Buserelin                   | Anti-cancer                                  | Under Development                          | —              |
| Atosiban                    | Halt premature labor                         | Commercial                                 | RoW            |

\* Developed for US/Eu/RoW markets.



## LIST OF SEMI-SYNTHETIC API



| Molecules*            | Therapeutic class                        | Stage                 | Commercial For |
|-----------------------|--|-----------------------|----------------|
| Micafungin Sodium     | Antifungal                               | Commercial            | RoW            |
| Anidulafungin         | Antifungal                               | Commercial            | RoW            |
| Everolimus            | Immunosuppressant                        | Pilot Scale completed | —              |
| Dalbavancin           | Antibacterial                            | Under Development     | —              |
| Obeticholic acid      | Treatment of Primary Biliary Cholangitis | Pilot Scale completed | —              |
| Midostaurin           | Anticancer                               | Pilot Scale completed | —              |
| Sarecycline           | Antibiotic                               | Pilot Scale completed | —              |
| Omadacycline          | Antibiotic                               | Under Development     | —              |
| Voclosporine          | Treatment of Lupus nephritis             | Under Development     | —              |
| Ibrexafungerp Citrate | Anti Fungal                              | Under Development     | —              |
| Rezafungin Acetate    | Anti Fungal                              | Under Development     | —              |

\* Developed for US/Eu/RoW markets.

## LIST OF OLIGONUCLEOTIDES

| Molecules* | Therapeutic class  | Stage          | Commercial For |
|------------|--|----------------|----------------|
| Nusinersen | Treatment of spinal muscular atrophy (SMA)   | Under Planning | —              |
| Patisiran  | Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults | Under Planning | —              |

\* For Development for US/Eu/RoW markets.

## LIST OF RECOMBINANT PEPTIDES

| Molecules*  | Therapeutic class     | Stage          | Commercial For |
|-------------|-----------------------|----------------|----------------|
| Semaglutide | Type II anti-Diabetic | Under planning | —              |
| Liraglutide | Type II anti-Diabetic | Under planning | —              |

\* For Development for US/Eu/RoW markets.



## LIST OF SYNTHETIC API

| Molecules*              | Therapeutic class                                    | Stage                 | Commercial For |
|-------------------------|--|-----------------------|----------------|
| Mebendazole, Form A     | Anthelmintic   | Commercial            | RoW            |
| Bedaquiline             | Antituberculosis                                     | Commercial            | RoW            |
| Sugammadex Sodium       | Reversal of neuromuscular blocker                    | Patent Out-licensed   | —              |
| Isavuconazonium sulfate | Antifungal   | Pilot Scale completed | —              |
| Remdesivir              | Antiviral  | Pilot Scale completed | —              |
| Nitisinone              | Hydroxy-phenylpyruvate dioxygenase inhibitor         | Pilot Scale completed | —              |
| Saroglitazar Mg         | Antidiabetic   | Under development     | —              |
| Deutetrabenazine        | Vesicular monoamine transporter 2 (VMAT2) inhibitors | Under development     | —              |
| Rufinamide              | Anti-epileptic                                       | Under development     | —              |
| Selexipag               | Prostacyclin receptor agonist                        | Under development     | —              |
| Vismodegib              | Hedgehog pathway inhibitor                           | Under development     | —              |
| Baricitinib             | Janus kinase (JAK) inhibitor                         | Under development     | —              |
| Apremilast              | Anti-psoriatic                                       | Under development     | —              |
| Brexanolone             | Antidepressant                                       | Under development     | —              |
| Brivaracetam            | Anti-epileptic                                       | Under development     | —              |
| Molnupiravir            | Anti-viral   | Under Development     | —              |
| Tetrabenazine           | Vesicular monoamine transporter 2 (VMAT) inhibitor   | Under Development     | —              |
| SNAC                    | Oral peptide absorption promoter                     | Under Development     | —              |
| Empagliflozin           | Antidiabetic   | Under development     | —              |
| Dapagliflozin           | Antidiabetic   | Under Development     | —              |
| Canagliflozin           | Antidiabetic   | Under Development     | —              |
| Pirfenidone             | Idiopathic pulmonary fibrosis                        | Under Development     | —              |
| Midodrine               | Vasoconstrictor, anti-hypotensive                    | Under Development     | —              |
| Crisaborole             | Anti-dermatitis                                      | Under Development     | —              |
| Fulvestrant             | Antineoplastic agent                                 | Under Development     | —              |
| Nintedanib Mesylate     | Anti-fibrosis  | Under Development     | —              |

\* Developed for US/Eu/RoW markets.



| Molecules*     | Therapeutic class   | Stage               | Commercial For |
|----------------|---|---------------------|----------------|
| Erdafitinib    | Anticancer  | Under Development   | —              |
| Isosulfan Blue | Adjunct to lymphography   | Under Development   | —              |
| Vonoprazan     | Potassium-competitive acid blocker (PCAB) for reducing acid secretion | Under development   | —              |
| Pretomanid     | Antimycobacterial   | Under development   | —              |
| Delamanid      | Antimycobacterial   | Under Development   | —              |
| Venetoclax     | Anticancer  | Under Development   | —              |
| Ribociclib     | Kinase inhibitor  | Under Development   | —              |
| Tedizolid      | Oxazolidinone antibiotics   | Under Development   | —              |
| Alogliptin     | Oral anti-diabetic drug   | Under development   | —              |
| Bempedoic acid | Hypercholesterolemia treatment  | Under development   | —              |
| Tavaborole     | Antifungal agent  | Under development   | —              |
| Vortioxetine   | Antidepressant  | Under development   | —              |
| Lifitegrast    | Dry eye treatment   | Dev to be initiated | —              |
| Binimetinib    | Anticancer  | Dev to be initiated | —              |
| Lumacaftor     | Treatment of cystic fibrosis  | Under development   | —              |
| Sotorasib      | Anti-cancer   | Under development   | —              |

\* Developed for US/Eu/RoW markets.



## List of Formulations under Development



### Liquid Injectables.

- Carbetocin injection 100 micrograms/mL in glass vials.
- Brexanolone injection, 100 mg brexanolone in 20 mL (5 mg/mL) aq. Solution.
- Sugammadex injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in a single-dose vial.
- Ganirelix Acetate injection in 1 mL prefilled glass syringes containing 250 mcg/0.5 mL as aqueous solution.



### Lyophilized Injections.

- Cetrorelix Acetate for injection: 0.25 mg cetrorelix/vial.
- Micafungin for injection, 50 mg micafungin (equivalent to 50.86 mg micafungin sodium) or 100 mg micafungin (equivalent to 101.73 mg micafungin sodium).
- Anidulafungin for injection, 50mg & 100 mg/vial.
- Degarelix for injection 120 mg of degarelix (equivalent to the median value of 126 mg degarelix acetate) and 80mg (equivalent to the median value of 84 mg degarelix acetate).



### Solid Orals tablets/ capsules.

- Sarecycline film coated tablets, 60 mg, 100 mg, and 150 mg.
- Saroglitazar Calcium tablets 2mg and 4mg.
- Everolimus tablet 0.25mg.



### Complex Generics (Oral Peptides).

- Semaglutide Tablets 3 mg, 7 mg, 14 mg.
- Linaclootide Hard Gelatin Capsule, 72 mcg, 145 mcg and 290 mcg.
- Plecanatide Tablets 3mg.















### Complex Novel Injectables.

- Triptorelin Acetate Microgranules injectable suspension 3.75mg per vial every 4 week, 11.25 mg per vial every 12 weeks; 22.5 mg per vial for every 24 weeks.
- Leuprorelin Acetate for depot suspension (lyophilized microspheres), 3.75 mg (1M), 7.5 mg (1M), 22.5 mg (3M), 30 mg (4M), and 45 mg (6M) per vial for injection.
- Octreotide Acetate lyophilized microspheres for injectable suspension, 10 mg, 20 mg or 30 mg per vial strength.



## LIST OF INTERMEDIATES

| Name of the Intermediate  | Structure of the compound   | CAS Number   | Name of API    | Status      |
|---|---|--------------|----------------|-------------|
| 2-((6-chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile                                 |    | 865758-96-9  | Alogliptin     | Scale up    |
| (R)-tert-butyl (1-(3-(2-cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)piperidin-3-yl)carbamate |    | 1246610-74-1 | Alogliptin     | Scale up    |
| 5-amino-3-(trifluoromethyl)picolinonitrile  |    | 573762-62-6  | Apalutamide    | R & D       |
| 4-amino-2-fluoro-N-methylbenzamide  |    | 915087-25-1  | Apalutamide    | R & D       |
| 4-((1-cyanocyclobutyl)amino)-2-fluoro-N-methylbenzamide   |    | 915087-26-2  | Apalutamide    | R & D       |
| N-(1,3-dioxo-1,3-dihydroisobenzofuran-4-yl)   |    | 6296-53-3    | Apremilast     | Commercial  |
| 2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulfonyl)eth-2-ylamine  |    | 253168-94-4  | Apremilast     | Commercial  |
| (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine   |    | 608141-42-0  | Apremilast     | Commercial  |
| 4''-(pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxylic acid   |  | 158938-08-0  | Anidulafungin  | Commercial  |
| tert-butyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate   |  | 1236033-21-8 | Baricitinib    | Scale-up    |
| 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]-   |  | 1919837-50-5 | Baricitinib    | Scale-up    |
| 3-benzyl-6-bromo-2-methoxyquinoline   |  | 654655-69-3  | Bedaquiline    | Commercial  |
| 3-(dimethylamino)-1-(naphthalen-1-yl)propan-1-one hydrochloride   |  | 5409-58-5    | Bedaquiline    | Commercial  |
| (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol               |  | 843663-66-1  | Bedaquiline    | Commercial  |
| N-(4-Bromophenyl)-benzenepropanamide  |  | 316146-27-7  | Bedaquiline    | Commercial  |
| Ethyl 7-bromo-2,2-dimethylheptanoate  |  | 123469-92-1  | Bempedoic acid | Development |
| Diethyl 8-isocyano-2,2,14,14-tetramethyl-8-tosylpentadecanedioate   |  | 738606-44-5  | Bempedoic acid | Development |
| 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid diethyl ester  |  | 738606-43-4  | Bempedoic acid | Development |
| 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid  |  | 413624-71-2  | Bempedoic acid | Development |

| Name of the Intermediate  | Structure of the compound | CAS Number    | Name of API                                     | Status     |
|---|---------------------------|---------------|---|------------|
| Methyl 4-amino-2,3-difluoro-5-nitrobenzoate   |                           | 284030-58-6   | Binimetinib                                     | Commercial |
| Methyl 4-amino-3-fluoro-2-((2-fluorophenyl)amino)-5-nitrobenzoate   |                           | 606143-94-6   | Binimetinib                                     | Commercial |
| 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate   |                           | 606143-48-0   | Binimetinib                                     | Commercial |
| Methyl 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-Methyl-1H-benzo[d]imidazole-6-carboxylate   |                           | 1415559-93-1  | Binimetinib                                     | Commercial |
| O-(2-tert-butoxy-ethyl)-hydroxylamine   |                           | 1023742-13-3  | Binimetinib                                     | Commercial |
| O-(2-vinyloxyethyl)-hydroxylamine   |                           | 391212-29-6   | Binimetinib                                     | Commercial |
| Isopregnanolone   |                           | 516-55-2      | Brexanolone                                     | Scale up   |
| 4-NO2Bz-allopregnanolone  |                           | Not Available | Brexanolone                                     | Scale up   |
| 1-(benzo[b]thiophen-4-yl)piperazine hydrochloride   |                           | 913614-18-3   | Brexipiperezole                                 | Scale up   |
| 7-(4-chlorobutoxy)quinolin-2(1H)-one  |                           | 913613-82-8   | Brexipiperezole                                 | Scale up   |
| 2-(5-bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene  |                           | 1030825-20-7  | Canagliflozin                                   | Commercial |
| (3R,4S,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol |                           | 1030825-21-8  | Canagliflozin                                   | Commercial |
| (2S,3R,4R,5S,6R)-2-[3-[5-[4-Fluoro-phenyl]-thiophen-2-ylmethyl]-4-methyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol           |                           | 842133-18-0   | Canagliflozin                                   | Commercial |
| (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one                                  |                           | 32384-65-9    | Canagliflozin<br>Dapagliflozin<br>Empagliflozin | Commercial |
| Ethyl trans-2-(4-Aminocyclohexyl)acetate Hydrochloride  |                           | 76308-26-4    | Cariprazine                                     | R&D        |
| Ethyl trans-2-(4-(3,3-dimethylureido)cyclohexyl) acetate  |                           | 1642586-63-7  | Cariprazine                                     | R&D        |
| 4-(4-bromo-3-(hydroxymethyl)phenoxy)benzonitrile  |                           | 906673-45-8   | Crisaborole                                     | Scale up   |
| 4-(4-bromo-3-((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenoxy)benzonitrile   |                           | 943311-78-2   | Crisaborole                                     | Scale up   |
| 4-((1-hydroxy-1,3-dihydrobenzo [c][1,2]oxaborol-5-yl)oxy)benzonitrile   |                           | 906673-24-3   | Crisaborole                                     | Scale up   |



| Name of the Intermediate  | Structure of the compound | CAS Number   | Name of API     | Status     |
|---|---------------------------|--------------|-----------------|------------|
| 5-bromo-2-chlorobenzoic acid  |                           | 21739-92-4   | Dapagliflozin   | Commercial |
| 4-(5-bromo-2-chlorobenzyl)phenol  |                           | 864070-18-8  | Dapagliflozin   | Commercial |
| 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene  |                           | 461432-23-5  | Dapagliflozin   | Commercial |
| (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol   |                           | 714269-57-5  | Dapagliflozin   | Scale up   |
| (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol  |                           | NA           | Dapagliflozin   | Commercial |
| (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 461432-   |                           | 461432-26-8  | Dapagliflozin   | Scale up   |
| 1,1'-([1,1'-biphenyl]-4,4'-diyl)bis(2-bromoethanone)  |                           | 4072-67-7    | Daclatasvir     | Commercial |
| 1,1'-([1,1'-biphenyl]-4,4'-diyl)bis(2-chloroethanone)   |                           | 24860-53-5   | Daclatasvir     | Commercial |
| N-Boc-L-Proline   |                           | 15761-39-4   | Daclatasvir     | Commercial |
| (S)-2-((Methoxycarbonyl)amino)-3-methylbutanoic acid  |                           | 74761-42-5   | Daclatasvir     | Commercial |
| 3,4-dihydroisoquinoline-6,7-diol hydrochloride  |                           | 4722-06-9    | Deutetabenazine | Commercial |
| Fmoc-L-Lys(Boc, i-Pr)-OH  |                           | 201003-48-7  | Degarelix       | Scale up   |
| Fmoc-L-Aph(L-Hor)-OH  |                           | 1253282-31-3 | Degarelix       | Scale up   |
| Fmoc-D-4-Aph(t-Bu-Cbm)-OH   |                           | 1433975-21-3 | Degarelix       | Scale up   |
| Dydrogesterone bis(Ethylene Acetal)   |                           | 5488-51-7    | Dydrogesterone  | Commercial |
| (-)N-Boc-D-α-phenylglycinol   |                           | 102089-74-7  | Elagolix        | R&D        |
| 5-bromo-1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-1H-pyrimidine-2,4-Dione   |                           | 830346-48-0  | Elagolix        | R&D        |
| tert-butyl N-[(1R)-2-(5-bromo-3-[(2-fluoro-6-(trifluoromethyl)phenyl)methyl]-4-methyl-2,6-dioxa-1,2,3,6-tetrahydropyrimidin-1-yl)-1-phenylethyl]carbamate   |                           | 830346-49-1  | Elagolix        | R&D        |
| 3-[(2R)-N-(tert-butoxycarbonyl)amino-2-phenylethyl]-2-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione |                           | 830346-51-5  | Elagolix        | Scale up   |



| Name of the Intermediate   | Structure of the compound | CAS Number   | Name of API   | Status     |
|--|---------------------------|--------------|---------------|------------|
| methyl (R)-4-(2-[5-(2-fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)butyrate |                           | 1092070-97-7 | Elagolix      | Scale up   |
| (S)-5-Phenylmorpholin-2-one hydrochloride  |                           | 491833-36-4  | Eliglustat    | Commercial |
| 2,3-Dihydro-1,4-benzodioxine-6-carbaldehyde  |                           | 29668-44-8   | Eliglustat    | Commercial |
| (1R,3S,5S,8aS)-1,3-Bis-(2',3'-dihydro-benzo[1,4]dioxin-6'-yl)-5-phenyl-tetrahydro-oxazolo[4,3-c][1,4]oxazin-8-one  |                           | 491833-25-1  | Eliglustat    | Scale up   |
| (S)-[1-(4-Phenyl-1H-imodazol-2-yl)- ethanamine   |                           | 864825-23-0  | Eluxadoline   | Scale up   |
| 5-Formyl-2-methoxyl-benzoic acid methyl ester  |                           | 78515-16-9   | Eluxadoline   | Scale up   |
| (S)-(5-bromo-2-chlorophenyl)(4-((tetrahydrofuran-3-yl)oxy)phenyl)methanone   |                           | 915095-84-0  | Empagliflozin | Commercial |
| (3S)-3-(4-(5-bromo-2-chlorobenzyl)phenoxy) tetrahydrofuran   |                           | 915095-89-5  | Empagliflozin | Commercial |
| (5-Bromo-2-chlorophenyl)(4-fluorophenyl) methanone   |                           | 915095-85-1  | Empagliflozin | Commercial |
| (S)-(2-chloro-5-iodophenyl)(4-((tetrahydrofuran-3-yl)oxy)phenyl)methanone  |                           | 915095-87-3  | Empagliflozin | Commercial |
| (3S)-3-(4-(2-chloro-5-iodobenzyl)phenoxy) tetrahydrofuran  |                           | 915095-94-2  | Empagliflozin | Commercial |
| (S)-tetrahydrofuran-3-ol   |                           | 86087-23-2   | Empagliflozin | Commercial |
| (S)-tetrahydrofuran-3-yl-4-methylbenzenesulfonate  |                           | 112052-11-6  | Empagliflozin | Commercial |
| (R)-tetrahydrofuran-3-ol   |                           | 86087-24-3   | Empagliflozin | Commercial |
| (R)-tetrahydrofuran-3-yl-4-methylbenzenesulfonate  |                           | 219823-47-9  | Empagliflozin | Commercial |
| 3,5-Dimethoxybenzamide   |                           | 17213-58-0   | Erdafitinib   | Commercial |
| 3,5-Dimethoxyaniline   |                           | 10272-07-8   | Erdafitinib   | Commercial |
| 7-Bromo-2-(1-methyl-1H-pyrazol-4-yl)-quinoxaline   |                           | 1083325-87-4 | Erdafitinib   | Commercial |
| 7-Bromoquinolin-2(1H)-one  |                           | 99465-10-8   | Erdafitinib   | Commercial |



| Name of the Intermediate  | Structure of the compound | CAS Number   | Name of API             | Status     |
|---|---------------------------|--------------|-------------------------|------------|
| 7-bromo-2-chloroquinoxaline   |                           | 89891-65-6   | Erdafitinib             | Commercial |
| N-(2-Chloroethyl)propan-2-amine hydrochloride   |                           | 6306-61-2    | Erdafitinib             | Commercial |
| 2-Isopropylaminoethanol   |                           | 109-56-8     | Erdafitinib             | Commercial |
| 9-((4,4,5,5,5-pentafluoropentyl)thio) nonan-1-ol  |                           | 511545-94-1  | Fulvestrant             | Scale up   |
| (9-iodononyl)(4,4,5,5,5-pentafluoropentyl)sulfane   |                           | 862700-63-8  | Fulvestrant             | Scale up   |
| S-Deoxo-6-oxo-fulvestrant   |                           | 1107606-70-1 | Fulvestrant             | Scale up   |
| S-Deoxo Fulvestrant   |                           | 153004-31-0  | Fulvestrant             | Scale up   |
| Fmoc-L-hArg(Et)2-OH HCl   |                           | 1864003-26-8 | Ganirelix               | Scale up   |
| Fmoc-D-hArg(Et)2-OH HCl   |                           | 208174-14-5  | Ganirelix               | Scale up   |
| 4-(2-hydroxyethyl)benzene-1,2-diol  |                           | 10597-60-1   | Hydroxytyrosol          | Scale up   |
| Isavuconazole   |                           | 241479-67-4  | Isavuconazonium sulfate | Scale up   |
| Boc-Isavuconazonium iodide  |                           | 338990-64-0  | Isavuconazonium sulfate | Scale up   |
| Benzofuran-6-carboxylic acid  |                           | 77095-51-3   | Lifitegrast             | Scale up   |
| 5,7-Dichloro-3,4-dihydro-2,6(1H)-isoquinolinedicarboxylic acid 2-(1,1-dimethylethyl)ester |                           | 851784-82-2  | Lifitegrast             | Scale up   |
| 5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid                    |                           | 1194550-56-5 | Lifitegrast             | Scale up   |
| 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic Acid Hydrochloride               |                           | 1289646-93-0 | Lifitegrast             | Commercial |
| (S)-tert-butyl 5-((2,5-dioxopyrrolidin-1-yl)oxy)-2-palmitamidopentanoate                  |                           | 204521-63-1  | Liraglutide             | Scale up   |
| (S)-methyl 5-((2,5-dioxopyrrolidin-1-yl)oxy)-2-palmitamidopentanoate                      |                           | 294855-90-6  | Liraglutide             | Scale up   |
| Fmoc-Thr(t-Bu)-Ser(t-Bu)-OH   |                           | 67436-14-0   | Liraglutide             | Scale up   |



| Name of the Intermediate  | Structure of the compound | CAS Number   | Name of API  | Status     |
|---|---------------------------|--------------|--------------|------------|
| (S)-5-((2,5-dioxopyrrolidin-1-yl)oxy)-2-palmitamidopentanoic acid   |                           | 294855-91-7  | Liraglutide  | Scale up   |
| N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-epsilon-(N-alpha'-palmitoyl-L-glutamic-acid alpha'-t-butyl ester)-L-lysine                           |                           | 1491158-62-3 | Liraglutide  | Scale up   |
| Fmoc-Arg(Pbf)-Gly-OH  |                           | 660846-80-0  | Liraglutide  | Scale up   |
| 6-bromo-5-methylpyridin-2-amine   |                           | 89466-17-1   | Lumacaftor   | Commercial |
| 6-Chloro-5-methylpyridin-2-amine  |                           | 442129-37-5  | Lumacaftor   | Commercial |
| 5-(4-bromophenyl)-4,6-dichloropyrimidine  |                           | 146533-41-7  | Macitentan   | Scale up   |
| N-5-(4-Bromophenyl)-6-chloro-4-pyrimidinyl-N'-propylsulfamide   |                           | 1393813-42-7 | Macitentan   | Scale up   |
| Methyl [5-benzoylbenzimidazole-2-yl] carbamate  |                           | 31431-39-7   | Mebendazole  | Commercial |
| 2-acetamido-4-chloro-5-sulfamoylbenzoic acid  |                           | 17560-54-2   | Metolazone   | Commercial |
| 4-(5-(4-(pentyloxy)phenyl)isoxazol-3-yl)benzoic acid  |                           | 179162-55-1  | Micafungin   | Commercial |
| 2-amino-1-(2,5-dimethoxyphenyl) ethanone hydrochloride  |                           | 671224-08-1  | Midodrine    | Scale up   |
| tert-butyl (2-((2,5-dimethoxyphenyl)-2-oxoethyl)amino)-2-oxoethyl)carbamate   |                           | 176851-43-7  | Midodrine    | Scale up   |
| 4-Amino-1-[(4R,6R)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]pyrimidin-2-one                             |                           | NA           | Molnupiravir | Scale up   |
| ((3aR,4R,6S,6aR)-6-(4-amino-2-oxypyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate                     |                           | NA           | Molnupiravir | Scale up   |
| 2',3'-O-Isopropylideneuridine   |                           | 362-43-6     | Molnupiravir | Scale up   |
| [(4R,6R)-4-[4-(hydroxyamino)-2-oxypyrimidin-1-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl 2-methylpropanoate      |                           | NA           | Molnupiravir | Scale up   |
| methyl (E)-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate   |                           | 1168150-46-6 | Nintedanib   | Scale up   |
| N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide  |                           | 262368-30-9  | Nintedanib   | Scale up   |
| Methyl (3Z)-3-{{[(4-(methyl[(4-methylpiperazin-1-yl)acetyl]amino)phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate} |                           | 656247-17-5  | Nintedanib   | Scale up   |



| Name of the Intermediate   | Structure of the compound | CAS Number   | Name of API               | Status     |
|--|---------------------------|--------------|---------------------------|------------|
| 2-nitro-4-(trifluoromethyl)benzoic acid  |                           | 320-94-5     | Nitisinone                | Commercial |
| (R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid  |                           | 459789-99-2  | Obeticholic acid          | Scale-up   |
| 2-Hydroxy-5-methylpyridine   |                           | 1003-68-5    | Pirfenidone               | Commercial |
| 5-Methyl-N-phenyl-2-1H-pyridone  |                           | 53179-13-8   | Pirfenidone               | Commercial |
| 1'-phenyl-[2,3'-bipyridin]-6'(1'H)-one   |                           | 381725-50-4  | Perampanel                | Scale up   |
| 3-bromo-1-phenyl-5-pyridin-2-ylpyridin-2-one   |                           | 381248-06-2  | Perampanel                | Scale up   |
| 2-(1,3,2-dioxaborinan-2-yl)benzonitrile  |                           | 172732-52-4  | Perampanel                | Scale up   |
| (3aR,4R,6R,6aR)-4-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-(hydroxymethyl)-2,2-dimethyl tetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile   |                           | 1191237-80-5 | Remdesivir                | Commercial |
| 2-Ethylbutyl (2S)-2-[[[(3aR,4R,6R,6aR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyl-6,6a-dihydro-3aH-furo[3,4-d][1,3]dioxol-6-yl]methoxy-phenoxyphosphoryl]amino]propanoate |                           | 1884576-18-4 | Remdesivir                | Commercial |
| 2-isocyanato-1,1'-biphenyl   |                           | 17337-13-2   | Remdesivir                | Scale up   |
| piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate   |                           | 171722-92-2  | Remdesivir                | R&D        |
| Benzyl methyl(2-oxoethyl)carbamate   |                           | 107201-33-2  | Remdesivir                | R&D        |
| benzyl (2,2-dimethoxyethyl)(methyl) carbamate  |                           | 1355573-66-8 | Remdesivir                | Commercial |
| (S,E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid  |                           | 180973-24-4  | Remdesivir                | Commercial |
| methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate   |                           | 1455091-10-7 | Roxadustat                | R&D        |
| methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate  |                           | 1421312-34-6 | Roxadustat                | R&D        |
| 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid   |                           | 166196-11-8  | Rufinamide                | Commercial |
| 6-Demethyl Tetracycline  |                           | NA           | Sarecycline Hydrochloride | Commercial |
| Sencycline   |                           | 808-62-4     | Sarecycline Hydrochloride | Commercial |





| Name of the Intermediate  | Structure of the compound | CAS Number   | Name of API                                   | Status     |
|---|---------------------------|--------------|---|------------|
| 7-Iodosancycline  |                           | 113164-67-3  | Sarecycline Hydrochloride                     | Commercial |
| (S)-2-Ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester  |                           | 222555-06-8  | Saroglitzazar                                 | Commercial |
| 2-{2-Methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrol-1-yl}ethan-1-ol   |                           | 494850-27-0  | Saroglitzazar                                 | Commercial |
| 5-chloro-2,3-diphenylpyrazine   |                           | 41270-66-0   | Selexipag                                     | Scale up   |
| 4-ISOPROPYLAMINOBUTANOL   |                           | 42042-71-7   | Selexipag                                     | Scale up   |
| Fmoc-L-Lys(Boc-AEEA)-OH   |                           | 1662688-16-5 | Semaglutide                                   | Scale up   |
| Fmoc-AEEAc-AEEAc-OH   |                           | 560088-89-3  | Semaglutide                                   | Scale up   |
| Octadecanedioic acid mono-tert-butyl ester  |                           | 843666-40-0  | Semaglutide                                   | Scale up   |
| Fmoc-L-Lys[OctotBu)-Glu-(otBu)-AEEA-AEEA]-OSu   |                           | 1118767-15-9 | Semaglutide                                   | Scale up   |
| Fmoc-L-Lys[OctotBu)-Glu-(otBu)-AEEA-AEEA]-OHu   |                           | 1118767-16-0 | Semaglutide                                   | Scale up   |
| Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH  |                           | 1662688-20-1 | Semaglutide                                   | Scale up   |
| Fmoc-AEEAc-AEEAc-OH   |                           | 560088-89-3  | Semaglutide                                   | Scale up   |
| H-AEEAc-OH  |                           | 134978-97-5  | Semaglutide                                   | Scale up   |
| 2-[2-(Fmoc-amino)ethoxy]ethanol   |                           | 299430-87-8  | Semaglutide                                   | Scale up   |
| Fmoc-His-Aib-OH   |                           | 1446013-07-5 | Semaglutide                                   | Scale up   |
| Fmoc-His-Aib-OSu  |                           | 1169631-12-2 | Semaglutide                                   | Scale up   |
| L-Alanine isopropyl ester hydrochloride   |                           | 62062-65-1   | Sofosbuvir, Tenofovir Alafenamide             | Commercial |
| 3-((Dimethylamino)methyl)-5-methylhexan-2-one   |                           | 91342-74-4   | Tetrabenazine / Deutetabenazine / Valbenazine | Commercial |
| (3aS,5R,6R,6aS)-6-((tert-butyldimethylsilyl)oxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde |                           | 1018898-77-5 | Sotagliflozin                                 | R&D        |



| Name of the Intermediate  | Structure of the compound | CAS Number    | Name of API                                       | Status     |
|---|---------------------------|---------------|---|------------|
| ((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(morpholino)methanone                  |                           | 1103738-19-7  | Sotagliflozin                                     | R&D        |
| 5-fluorobenzo[c][1,2]oxaborol-1(3H)-ol  |                           | 174671-46-6   | Tavaborole  | Scale up   |
| (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one  |                           | 444335-16-4   | Tavaborole  | Scale up   |
| 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine   |                           | 380380-64-3   | Tavaborole  | Scale up   |
| (R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one              |                           | 856867-55-5   | Tavaborole  | Scale up   |
| 3-((dimethylamino)methyl)-5-methylhexan-2-one methiodide  |                           | 1069-62-1     | Tetrabenazine/<br>Deutetabenazine/<br>Valbenazine | Commercial |
| 3-((dimethylamino)methyl)-5-methylhexan-2-one, oxalate  |                           | 2102090-17-3  | Tetrabenazine/<br>Deutetabenazine/<br>Valbenazine | Commercial |
| 6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride   |                           | 20232-39-7    | Tetrabenazine/<br>Deutetabenazine/<br>Valbenazine | Commercial |
| 6,7-dihydroxy-3,4-dihydroisoquinoline   |                           | 4602-83-9     | Deutetabenazine/<br>Valbenazine                   | Commercial |
| Fmoc-Lys(tBu-OOC-C18-CO-Glu(AEEA-AEEA)-OtBu)-OH   |                           | 2460751-66-8  | Tirzepatide                                       | Scale up   |
| tBu-OOC-C18-CO-Glu(AEEA-AEEA-OH)-OtBu   |                           | Not available | Tirzepatide                                       | Scale up   |
| Ethyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoate   |                           | 1630101-74-4  | Venetoclax  | Scale up   |
| 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride                |                           | 1628047-87-9  | Venetoclax  | Scale up   |
| 3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide   |                           | 1228779-96-1  | Venetoclax  | Scale up   |
| 2-chloro-4-(methylsulfonyl) benzoic acid  |                           | 53250-83-2    | Vismodegib  | R&D        |
| 2-(2-chloro-5-nitrophenyl) pyridine   |                           | 879088-40-1   | Vismodegib  | R&D        |
| 4-chloro-3-(pyridin-2-yl)aniline  |                           | 879088-41-2   | Vismodegib  | R&D        |
| 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide  |                           | 879085-55-9   | Vismodegib  | R&D        |
| 2-((2S,3R,4S,5R)-2,3,4-tris(benzyloxy)-5-((benzyloxy)methyl)-5-hydroxycyclohexyl)amino)propane-1,3-diolhydrobromide |                           | 1071985-27-7  | Voglibose   | Commercial |



| Name of the Intermediate  | Structure of the compound   | CAS Number  | Name of API  | Status   |
|---|---|-------------|--------------|----------|
| 1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]piperazine                          |  | 508233-74-7 | Vortioxetine | Scale up |
| 6-(5-chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-one |  | 43200-81-3  | Zopiclone    | Scale up |

